Liu Qianqian, Liu Hui, Zhang Sizhe, Yang Qijie, Shen Lu, Jiao Bin
Department of Neurology, Xiangya Hospital, Central South University, Changsha, China.
National Clinical Research Center for Geriatric Disorders, Central South University, Changsha, China.
J Alzheimers Dis. 2022;89(1):121-132. doi: 10.3233/JAD-215696.
Several studies have shown increased levels of cerebrospinal fluid (CSF) synaptosomal-associated protein 25 (SNAP-25) in patients with Alzheimer's disease (AD). However, results have been inconsistent thus far.
We conducted meta-analyses summarizing the associations of CSF SNAP-25 levels with AD to assess the utility of SNAP-25 as a novel biomarker for AD.
We conducted a meta-analysis of differences in CSF SNAP-25 levels in patients with AD or mild cognitive impairment (MCI) and in cognitively healthy controls (HC). We calculated pooled correlation coefficients comparing SNAP-25 levels and total tau (T-tau) or hyperphosphorylated tau (P-tau) in CSF.
Eight studies enrolling 1,162 individuals (423 AD, 275 MCI, 464 HC) were included for quantitative analysis. Patients with AD (ratio of means [RoM] = 1.50, 95% confidence interval [CI]: 1.30,1.74) and MCI (RoM = 1.45, 95% CI: 1.12,1.87) had increased levels of CSF SNAP-25 as compared to HC. The difference in CSF SNAP-25 levels when comparing AD and MCI (RoM = 1.05, 95% CI: 0.96,1.14) was not statistically significant but showed a trend toward significance. Statistically significant correlations were found when comparing CSF SNAP-25 with CSF T-tau (Spearman correlation coefficient, ρ=0.78; ρ=0.66; ρ=0.69, respectively) and P-tau (ρ=0.77; ρ=0.70; ρ=0.62, respectively) levels in patients with AD, MCI, and HC.
Increased CSF SNAP-25 levels differentiated patients with AD or MCI from controls, suggesting the utility of this biomarker in the early diagnosis of AD.
多项研究表明，阿尔茨海默病（AD）患者脑脊液（CSF）中突触体相关蛋白25（SNAP - 25）水平升高。然而，迄今为止结果并不一致。
我们进行了荟萃分析，总结脑脊液SNAP - 25水平与AD的关联，以评估SNAP - 25作为AD新型生物标志物的效用。
我们对AD或轻度认知障碍（MCI）患者以及认知健康对照（HC）的脑脊液SNAP - 25水平差异进行了荟萃分析。我们计算了比较脑脊液中SNAP - 25水平与总tau蛋白（T - tau）或磷酸化tau蛋白（P - tau）的合并相关系数。
纳入八项研究，共1162例个体（423例AD患者、275例MCI患者、464例HC）进行定量分析。与HC相比，AD患者（均值比[RoM] = 1.50，95%置信区间[CI]：1.30，1.74）和MCI患者（RoM = 1.45，95% CI：1.12，1.87）的脑脊液SNAP - 25水平升高。比较AD和MCI时脑脊液SNAP - 25水平的差异（RoM = 1.05，95% CI：0.96，1.14）无统计学意义，但显示出显著趋势。在AD、MCI患者及HC中，比较脑脊液SNAP - 25与脑脊液T - tau（Spearman相关系数分别为ρ = 0.78；ρ = 0.66；ρ = 0.69）和P - tau（ρ = 0.77；ρ = 0.70；ρ = 0.62）水平时，发现具有统计学意义的相关性。
脑脊液SNAP - 25水平升高可将AD或MCI患者与对照组区分开来，表明该生物标志物在AD早期诊断中的效用。
